AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study 14520129 — intervention group
Group type: EXPERIMENTAL
Intervention: Imipramine
Number of subjects: 40
Study 14520129 — intervention group
Group type: EXPERIMENTAL
Intervention: Buspirone
Number of subjects: 40
Study 14520129 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 40
Study 14520129 — intervention group
Group type: EXPERIMENTAL
Intervention: All treatments (Imipramine, Buspirone, Placebo)
Number of subjects: 40
Study 14698074 — intervention group
Group type: EXPERIMENTAL
Intervention: 10 mg mifepristone
Number of subjects: 6083
Study 10651259 — intervention group
Group type: EXPERIMENTAL
Intervention: UCP2 insertion variant
Number of subjects: 744
Study 10651259 — intervention group
Group type: COMPARATOR
Intervention: Control group (no UCP2 insertion variant)
Number of subjects: 744
Study 7899651 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.5 mg) in Group C0.5
Number of subjects: 45
Study 7899651 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.5 mg) in Group A0.5
Number of subjects: 45
Study 7899651 — intervention group
Group type: COMPARATOR
Intervention: Subcutaneous morphine in Group C0
Number of subjects: 45
Study 7899651 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.5 mg) in Groups C0.5 and A0.5
Number of subjects: 45
Study 7899651 — intervention group
Group type: EXPERIMENTAL
Intervention: Intrathecal morphine (0.5 mg)
Number of subjects: 45
Study 2693031 — intervention group
Group type: EXPERIMENTAL
Intervention: Triflusal (platelet antiaggregant drug)
Number of subjects: 17
Study 2693031 — intervention group
Group type: COMPARATOR
Intervention: Control group (no treatment)
Number of subjects: 17
Study 2693031 — intervention group
Group type: EXPERIMENTAL
Intervention: Both groups
Number of subjects: 17
Study 1263176 — intervention group
Group type: EXPERIMENTAL
Intervention: Free collection service for transporting specimens and results
Number of subjects: 0
Study 1263176 — intervention group
Group type: COMPARATOR
Intervention: Control group of general practitioners
Number of subjects: 0
Study 31421670 — intervention group
Group type: EXPERIMENTAL
Intervention: MOFA (0.2 g/kg fish oil preoperatively, followed by 48 h continuous infusion of 0.2 g/kg/d n3FA)
Number of subjects: 100
Study 31421670 — intervention group
Group type: COMPARATOR
Intervention: Control (standard ERAS therapy)
Number of subjects: 100
Study 27893184 — intervention group
Group type: EXPERIMENTAL
Intervention: Antidepressants and antipsychotics (specific drugs not detailed)
Number of subjects: 728
Study 27893184 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotropic drugs with cardiovascular risk
Number of subjects: 728
Study 27893184 — intervention group
Group type: EXPERIMENTAL
Intervention: Psychotropic drugs
Number of subjects: 728
Study 27893184 — intervention group
Group type: EXPERIMENTAL
Intervention: CACNA1C rs1006737 SNP
Number of subjects: 728
Study 27893184 — intervention group
Group type: EXPERIMENTAL
Intervention: Risk drugs
Number of subjects: 728
Study 27893184 — intervention group
Group type: EXPERIMENTAL
Intervention: CACNA1C rs1006737
Number of subjects: 728
Study 26003273 — intervention group
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa (150 μg single injection)
Number of subjects: 1390
Study 26003273 — intervention group
Group type: COMPARATOR
Intervention: Recombinant FSH (300 IU daily for first 7 days, then daily until three follicles reach ≥17 mm)
Number of subjects: 1390
Study 26003273 — intervention group
Group type: EXPERIMENTAL
Intervention: Corifollitropin alfa
Number of subjects: 1390
Study 26003273 — intervention group
Group type: COMPARATOR
Intervention: Recombinant FSH
Number of subjects: 1390
Study 23880960 — intervention group
Group type: EXPERIMENTAL
Intervention: Aspirin 600 mg/day
Number of subjects: 937
Study 23880960 — intervention group
Group type: EXPERIMENTAL
Intervention: Resistant starch 30 g/day
Number of subjects: 937
Study 23880960 — intervention group
Group type: COMPARATOR
Intervention: Control (no aspirin or resistant starch)
Number of subjects: 937
Study 20659577 — intervention group
Group type: EXPERIMENTAL
Intervention: Combined treatment with formoterol (FOR) 12 μg BID plus tiotropium (TIO) 18 μg QD
Number of subjects: 255
Study 20659577 — intervention group
Group type: COMPARATOR
Intervention: Tiotropium (TIO) alone 18 μg QD
Number of subjects: 255
Study 19812401 — intervention group
Group type: EXPERIMENTAL
Intervention: Doxycycline 200 mg daily for 6 weeks
Number of subjects: 216
Study 19812401 — intervention group
Group type: COMPARATOR
Intervention: No treatment
Number of subjects: 216
Study 17967584 — intervention group
Group type: EXPERIMENTAL
Intervention: Simvastatin 80 mg daily
Number of subjects: 12064
Study 17967584 — intervention group
Group type: EXPERIMENTAL
Intervention: Folic acid 2 mg plus vitamin B12 1 mg daily
Number of subjects: 12064
Study 17967584 — intervention group
Group type: COMPARATOR
Intervention: Matching placebo for homocysteine lowering
Number of subjects: 12064
Study 17967584 — intervention group
Group type: COMPARATOR
Intervention: Simvastatin 20 mg daily
Number of subjects: 12064
Study 17967584 — intervention group
Group type: EXPERIMENTAL
Intervention: Overall treatment
Number of subjects: 12064
Study 15479217 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide MR (30-120 mg) once daily
Number of subjects: 800
Study 15479217 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide MR in combination therapy
Number of subjects: 800
Study 15479217 — intervention group
Group type: EXPERIMENTAL
Intervention: Gliclazide MR
Number of subjects: 800
Study 11242646 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose group: MMC at 8 mg/m2 on the day of surgery, and in weeks 4, 10, 16, and 22 after surgery; 6 capsules of UFT (600 mg in tegafur) daily for 6 months.
Number of subjects: 1410
Study 11242646 — intervention group
Group type: COMPARATOR
Intervention: Low-dose group: MMC at 8 mg/m2 on the day of surgery; 3 capsules of UFT (300 mg in tegafur) daily for 6 months.
Number of subjects: 1410
Study 11242646 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose group
Number of subjects: 1410
Study 11242646 — intervention group
Group type: COMPARATOR
Intervention: Low-dose group
Number of subjects: 1410
Study 9564282 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic inspiratory muscle training (IMT) using a threshold trainer for 30 min/day for 2 weeks, 1 month before operation (group A)
Number of subjects: 84
Study 9564282 — intervention group
Group type: COMPARATOR
Intervention: Sham training (group B)
Number of subjects: 84
Study 9564282 — intervention group
Group type: EXPERIMENTAL
Intervention: Prophylactic inspiratory muscle training (IMT)
Number of subjects: 84
Study 7996525 — intervention group
Group type: EXPERIMENTAL
Intervention: Programmable subcutaneous infusion pump with terbutaline, adjusted to control uterine contraction frequency to < or = 4 contractions per hour.
Number of subjects: 32
Study 7996525 — intervention group
Group type: COMPARATOR
Intervention: Oral terbutaline, average of 6.5 mg every four to six hours.
Number of subjects: 32
Study 3396249 — intervention group
Group type: EXPERIMENTAL
Intervention: Nandrolone decanoate (100 mg IM bi-weekly for six months)
Number of subjects: 20
Study 3396249 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 20
Study 31356008 — intervention group
Group type: EXPERIMENTAL
Intervention: Serenoa repens extract (ESR - Permixon) 320 mg capsules per day for two years
Number of subjects: 155
Study 31356008 — intervention group
Group type: EXPERIMENTAL
Intervention: Mathematical models built using predictive analytics
Number of subjects: 155
Study 28367765 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus HN001 (6×10^9 colony-forming units)
Number of subjects: 423
Study 28367765 — intervention group
Group type: EXPERIMENTAL
Intervention: Lactobacillus rhamnosus HN001
Number of subjects: 423
Study 28367765 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 423
Study 25817289 — intervention group
Group type: EXPERIMENTAL
Intervention: Rice bran extract containing acylated steryl glucosides (RB‐ASG)
Number of subjects: 51
Study 25817289 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 51
Study 24012053 — intervention group
Group type: EXPERIMENTAL
Intervention: 5-day course of amoxicillin/clavulanic acid 625 mg orally every 8 h for 4 days after 24 h of intravenous administration
Number of subjects: 62
Study 24012053 — intervention group
Group type: COMPARATOR
Intervention: 1-day course of amoxicillin/clavulanic acid 1.2 g intravenously for 24 h followed by oral placebo
Number of subjects: 62
Study 22082795 — intervention group
Group type: EXPERIMENTAL
Intervention: Compression Garments (CGs)
Number of subjects: 25
Study 22082795 — intervention group
Group type: COMPARATOR
Intervention: Running Shorts
Number of subjects: 25
Study 20027661 — intervention group
Group type: EXPERIMENTAL
Intervention: RVOT pacing
Number of subjects: 96
Study 20027661 — intervention group
Group type: COMPARATOR
Intervention: RVA pacing
Number of subjects: 96
Study 16462483 — intervention group
Group type: EXPERIMENTAL
Intervention: Neurolysis in situ
Number of subjects: 44
Study 16462483 — intervention group
Group type: COMPARATOR
Intervention: Submuscular transposition
Number of subjects: 44
Study 15000513 — intervention group
Group type: EXPERIMENTAL
Intervention: Acamprosate (1.998 mg/day)
Number of subjects: 75
Study 15000513 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 75
Study 11777099 — intervention group
Group type: EXPERIMENTAL
Intervention: Aerosolized ribavirin for 5 days
Number of subjects: 25
Study 9135305 — intervention group
Group type: EXPERIMENTAL
Intervention: Propofol
Number of subjects: 20
Study 9135305 — intervention group
Group type: COMPARATOR
Intervention: Control (Thiopentone and Isoflurane)
Number of subjects: 20
Study 7908821 — intervention group
Group type: EXPERIMENTAL
Intervention: isoflurane
Number of subjects: 86
Study 7908821 — intervention group
Group type: EXPERIMENTAL
Intervention: sevoflurane
Number of subjects: 86
Study 7908821 — intervention group
Group type: COMPARATOR
Intervention: discontinuation of both anaesthetics
Number of subjects: 86
Study 3282069 — intervention group
Group type: EXPERIMENTAL
Intervention: Participation of volunteer clinical faculty members in education research projects
Number of subjects: 76
Study 31714531 — intervention group
Group type: EXPERIMENTAL
Intervention: CABG in young patients
Number of subjects: 175
Study 31714531 — intervention group
Group type: COMPARATOR
Intervention: CABG in older patients (control group)
Number of subjects: 175
Study 28775674 — intervention group
Group type: EXPERIMENTAL
Intervention: Individualized fluid plans (IFPs)
Number of subjects: 11
Study 28775674 — intervention group
Group type: COMPARATOR
Intervention: Ad libitum fluid ingestion (CON)
Number of subjects: 11
Study 24959663 — intervention group
Group type: EXPERIMENTAL
Intervention: Ferrous asparto glycinate
Number of subjects: 73
Study 24959663 — intervention group
Group type: COMPARATOR
Intervention: Ferrous ascorbate
Number of subjects: 73
Study 22696144 — intervention group
Group type: EXPERIMENTAL
Intervention: Group LM (19 ml of 0.25% levobupivacaine and 1 ml of 15% magnesium sulphate)
Number of subjects: 107
Study 22696144 — intervention group
Group type: EXPERIMENTAL
Intervention: Group LM
Number of subjects: 107
Study 22696144 — intervention group
Group type: COMPARATOR
Intervention: Group L (20 ml of 0.25% levobupivacaine)
Number of subjects: 107
Study 21666991 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to blue light followed by red light
Number of subjects: 12
Study 21666991 — intervention group
Group type: EXPERIMENTAL
Intervention: Exposure to red light followed by blue light
Number of subjects: 12
Study 21666991 — intervention group
Group type: COMPARATOR
Intervention: Exposure to red light (previous study)
Number of subjects: 12
Study 17937959 — intervention group
Group type: EXPERIMENTAL
Intervention: 4 mg fesoterodine
Number of subjects: 836
Study 17937959 — intervention group
Group type: EXPERIMENTAL
Intervention: 8 mg fesoterodine
Number of subjects: 836
Study 17937959 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 836
Study 15731540 — intervention group
Group type: EXPERIMENTAL
Intervention: Mucosal protection (teprenone 150 mg/day)
Number of subjects: 210
Study 15731540 — intervention group
Group type: EXPERIMENTAL
Intervention: Histamine2-receptor antagonist (ranitidine 300 mg/day)
Number of subjects: 210
Study 15731540 — intervention group
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor (rabeprazole 10 mg/day)
Number of subjects: 210
Study 11755937 — intervention group
Group type: EXPERIMENTAL
Intervention: tibolone 2.5 mg/day (n=20)
Number of subjects: 43
Study 11755937 — intervention group
Group type: COMPARATOR
Intervention: 0.625 mg/day conjugated equine oestrogens plus continuous medroxyprogesterone acetate 5 mg/day (n=23)
Number of subjects: 43
Study 9652276 — intervention group
Group type: EXPERIMENTAL
Intervention: In-line intravenous filters
Number of subjects: 88
Study 9652276 — intervention group
Group type: COMPARATOR
Intervention: No in-line intravenous filters
Number of subjects: 88
Study 7808565 — intervention group
Group type: EXPERIMENTAL
Intervention: Amitriptyline 75 mg (slow-release formulation)
Number of subjects: 0
Study 7808565 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study 2675302 — intervention group
Group type: EXPERIMENTAL
Intervention: Low-dose antacid regimen
Number of subjects: 47
Study 4406985 — intervention group
Group type: EXPERIMENTAL
Intervention: Lillehei Kaster pivoting disc valve
Number of subjects: 68
Study 4406985 — intervention group
Group type: COMPARATOR
Intervention: Bjork Shiley tilting disc valve
Number of subjects: 68
Study 31913908 — intervention group
Group type: EXPERIMENTAL
Intervention: 13-valent pneumococcal conjugate vaccine (PCV13)
Number of subjects: 0
Study 29667598 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-guided transcranial focused ultrasound (FUS) at 650 kHz
Number of subjects: 128
Study 29667598 — intervention group
Group type: EXPERIMENTAL
Intervention: MR-guided transcranial focused ultrasound (FUS)
Number of subjects: 128
Study 26118386 — intervention group
Group type: EXPERIMENTAL
Intervention: High-dose tranexamic acid (4 g intravenously then 1 g/h for 6 h)
Number of subjects: 289
Study 24781936 — intervention group
Group type: EXPERIMENTAL
Intervention: Visual Field Reading Center evaluation of baseline visual fields
Number of subjects: 165
Study 22695134 — intervention group
Group type: EXPERIMENTAL
Intervention: Weekly UV-B in a tanning bed (group A)
Number of subjects: 30
Study 22695134 — intervention group
Group type: EXPERIMENTAL
Intervention: 1520-IU/d vitamin D supplement (group B)
Number of subjects: 30
Study 22695134 — intervention group
Group type: COMPARATOR
Intervention: Placebo (group C)
Number of subjects: 30
Study 21036840 — intervention group
Group type: EXPERIMENTAL
Intervention: Structured observation
Number of subjects: 45
Study 21036840 — intervention group
Group type: COMPARATOR
Intervention: Pre-observation days
Number of subjects: 45
Study 18946298 — intervention group
Group type: EXPERIMENTAL
Intervention: 7 mg spinal bupivacaine with intravenous phenylephrine infusion (0.25 microg . kg(‐1) . min(‐1))
Number of subjects: 80
Study 18946298 — intervention group
Group type: COMPARATOR
Intervention: 10 mg spinal bupivacaine with intravenous placebo infusion
Number of subjects: 80
Study 15671072 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin microemulsion
Number of subjects: 20
Study 15671072 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin plus metabolites
Number of subjects: 20
Study 15671072 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin
Number of subjects: 20
Study 15671072 — intervention group
Group type: EXPERIMENTAL
Intervention: Cyclosporin metabolites AM1, AM9, AM1c, AM4n
Number of subjects: 20
Study 12824967 — intervention group
Group type: EXPERIMENTAL
Intervention: Immediate colposcopy
Number of subjects: 3488
Study 12824967 — intervention group
Group type: EXPERIMENTAL
Intervention: HPV triage strategy
Number of subjects: 3488
Study 12824967 — intervention group
Group type: EXPERIMENTAL
Intervention: Conservative management strategy (repeat cytology at HSIL threshold)
Number of subjects: 3488
Study 11938811 — intervention group
Group type: EXPERIMENTAL
Intervention: Yimai Jiangya extract (YMJYE)
Number of subjects: 68
Study 11938811 — intervention group
Group type: COMPARATOR
Intervention: Captopril (control)
Number of subjects: 68
Study 8857917 — intervention group
Group type: EXPERIMENTAL
Intervention: Medium cholesterol diet (350 mg)
Number of subjects: 30
Study 8857917 — intervention group
Group type: EXPERIMENTAL
Intervention: High cholesterol diet (650 mg)
Number of subjects: 30
Study 1638340 — intervention group
Group type: EXPERIMENTAL
Intervention: Trichlormethiazide (4 mg/day)
Number of subjects: 175
Study 1638340 — intervention group
Group type: COMPARATOR
Intervention: Control (no treatment with close follow-up)
Number of subjects: 175
Study 6594721 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg PGE2 gel placed retroamnially by means of a balloon catheter
Number of subjects: 0
Study 6594721 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.4 mg PGE2 applied endocervically
Number of subjects: 0
Study 6594721 — intervention group
Group type: EXPERIMENTAL
Intervention: 0.5 mg PGE2 applied endocervically
Number of subjects: 0
Study 6594721 — intervention group
Group type: EXPERIMENTAL
Intervention: 3 mg PGE2 placed intravaginally in form of a single vaginal tablet
Number of subjects: 0
Study 6594721 — intervention group
Group type: COMPARATOR
Intervention: Control group (only vaginal examination)
Number of subjects: 0
Study 30892283 — intervention group
Group type: EXPERIMENTAL
Intervention: Navigation group (preoperative virtual planning)
Number of subjects: 29
Study 30892283 — intervention group
Group type: COMPARATOR
Intervention: Non-navigation group (no preoperative virtual planning)
Number of subjects: 29
Study 29242281 — intervention group
Group type: EXPERIMENTAL
Intervention: Osimertinib 80 mg once daily
Number of subjects: 419
Study 29242281 — intervention group
Group type: COMPARATOR
Intervention: Chemotherapy (control)
Number of subjects: 419
Study 26892451 — intervention group
Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 490
Study 26892451 — intervention group
Group type: COMPARATOR
Intervention: Local Anesthesia with Sedation (non-GA)
Number of subjects: 490
Study 25522424 — intervention group
Group type: EXPERIMENTAL
Intervention: Catecholamine depletion with alpha‐methyl‐para‐tyrosine (AMPT)
Number of subjects: 47
Study 25522424 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 47
Study 25522424 — intervention group
Group type: EXPERIMENTAL
Intervention: Catecholamine depletion
Number of subjects: 47
Study 25522424 — intervention group
Group type: EXPERIMENTAL
Intervention: Standardized breakfast (before and after)
Number of subjects: 47
Study 22278334 — intervention group
Group type: EXPERIMENTAL
Intervention: CG100649 (2 mg)
Number of subjects: 23
Study 22278334 — intervention group
Group type: EXPERIMENTAL
Intervention: CG100649 (8 mg)
Number of subjects: 23
Study 22278334 — intervention group
Group type: EXPERIMENTAL
Intervention: Celecoxib (200 mg)
Number of subjects: 23
Study 22278334 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 23
Study 21125532 — intervention group
Group type: EXPERIMENTAL
Intervention: PRISM (Pictorial Representation of Illness and Self Measure)
Number of subjects: 3
Study 17353132 — intervention group
Group type: EXPERIMENTAL
Intervention: Automatic morphometric cartilage quantification using MRI
Number of subjects: 0
Study 17353132 — intervention group
Group type: EXPERIMENTAL
Intervention: Cartilage Curvature quantification
Number of subjects: 0
Study 17353132 — intervention group
Group type: EXPERIMENTAL
Intervention: Joint Space Width (JSW)
Number of subjects: 0
Study 16288118 — intervention group
Group type: EXPERIMENTAL
Intervention: Tamoxifen
Number of subjects: 13388
Study 16288118 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 13388
Study 11882552 — intervention group
Group type: EXPERIMENTAL
Intervention: 42 day reducing course of dexamethasone (long course)
Number of subjects: 76
Study 11882552 — intervention group
Group type: COMPARATOR
Intervention: 3 day pulsed course of dexamethasone (pulse course)
Number of subjects: 76
Study 11882552 — intervention group
Group type: EXPERIMENTAL
Intervention: Both courses of dexamethasone
Number of subjects: 76
Study 10075616 — intervention group
Group type: EXPERIMENTAL
Intervention: Inhaled beclomethasone, 200 microg twice daily
Number of subjects: 895
Study 10075616 — intervention group
Group type: EXPERIMENTAL
Intervention: Oral montelukast, 10 mg once daily at bedtime
Number of subjects: 895
Study 10075616 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 895
Study 7734138 — intervention group
Group type: EXPERIMENTAL
Intervention: Intravenous infusion of tyramine to raise systemic blood pressure
Number of subjects: 30
Study 1755532 — intervention group
Group type: COMPARATOR
Intervention: Patient Controlled Analgesia (PCA) with morphine (2 mg bolus, lock-out 5 min in recovery/intensive care, 15 min in surgical ward)
Number of subjects: 292
Study 1755532 — intervention group
Group type: EXPERIMENTAL
Intervention: Epidural Bupivacaine + Morphine (EBM) with bupivacaine (0.25%) and morphine (60 micrograms/ml) infused via epidural catheter for approximately 72 hours
Number of subjects: 292
Study 1755532 — intervention group
Group type: COMPARATOR
Intervention: Epidural Morphine (EM) with morphine (0.05 mg/kg in 10 ml saline) injected on request up to the 3rd postoperative day
Number of subjects: 292
Study 6120272 — intervention group
Group type: EXPERIMENTAL
Intervention: Sulphinpyrazone 400 mg twice daily
Number of subjects: 727
Study 6120272 — intervention group
Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 727
Study 31794936 — intervention group
Group type: EXPERIMENTAL
Intervention: incobotulinumtoxinA 75 U
Number of subjects: 184
Study 31794936 — intervention group
Group type: EXPERIMENTAL
Intervention: incobotulinumtoxinA 100 U
Number of subjects: 184
Study 31794936 — intervention group
Group type: COMPARATOR
Intervention: placebo
Number of subjects: 184
Study 31063659 — intervention group
Group type: EXPERIMENTAL
Intervention: Fluid Immersion Simulation System (FIS)
Number of subjects: 40
Study 29610038 — intervention group
Group type: EXPERIMENTAL
Intervention: GP education session
Number of subjects: 291
Study 26595551 — intervention group
Group type: EXPERIMENTAL
Intervention: Influenza vaccine at the time of infliximab infusion
Number of subjects: 137
Study 26595551 — intervention group
Group type: COMPARATOR
Intervention: Influenza vaccine midway between infliximab infusions
Number of subjects: 137
Study 23471234 — intervention group
Group type: EXPERIMENTAL
Intervention: Recombinant t-PA (0, 40, 200, and 1000 ng/mL)
Number of subjects: 20
Study 23471234 — intervention group
Group type: EXPERIMENTAL
Intervention: Intra-arterial bradykinin infusion
Number of subjects: 20